Early detection and prevention of cancer can save lives, but current tools often fall short because of suboptimal accuracy and limited accessibility. The Fred Hutch Cancer Center aims to change that ...
A new plasmonic sensor developed by researchers at the University of Illinois at Urbana-Champaign will serve as a reliable early detection of biomarkers for many forms of cancer and eventually other ...
Metastatic breast cancer subtypes and biomarkers are crucial for guiding treatment decisions and managing disease progression. ER-positive, HER2-negative breast cancer treatment often begins with ...
Despite the clinical utility of biomarker testing in patients with prostate cancer, the tests are infrequently ordered, preventing optimized care. Despite guideline recommendations and the efficacy of ...
Biomarker testing can help shape more effective treatment regimens for lung cancer, helping patients avoid ineffective, less-targeted approaches, but it still isn’t used to its full potential for high ...
A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are emerging as important for guiding ovarian cancer therapy, including ...
Dr. Sita Kugel’s team recently published two papers identifying a key biological signature that not only provides clinics a faster, cheaper way to tell pancreatic cancer subtypes apart, but reveals a ...
Only 35% of advanced cancer patients received comprehensive genomic profiling testing. Tested patients were more likely to receive targeted therapies. Testing rates increased slightly over time and ...
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Food and Drug Administration (FDA) approval of its in vitro diagnostic (IVD) TruSight™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback